Literature DB >> 2850923

Buprenorphine is a potent kappa-opioid receptor antagonist in pigeons and mice.

J D Leander1.   

Abstract

Buprenorphine was studied for its antagonist activity against the specific kappa-opioid agonist U-50,488H in pigeons responding under a multiple schedule of grain presentation and in mice in an antinociception test. U-50,488H decreased rates of responding of pigeons over the dose range (2.5-20 mg/kg i.m.). In the presence of 0.32 mg/kg of buprenorphine, the U-50,488H dose-effect curve was shifted to the right approximately two-fold. Buprenorphine alone (0.01-0.08 mg/kg s.c.) inhibited in mice the abdominal stretching induced by i.p. acetic acid. beta-Funaltrexamine pretreatment blocked the mu-like agonist analgesic effect of buprenorphine and revealed an antagonist action of buprenorphine against 2.5 mg/kg of U-50,488H over the same dose range that it produced antinociception at the mu-receptor. Thus, buprenorphine is a potent kappa-opioid receptor antagonist, producing the kappa-antagonist activity over the same dose range that it produces its mu-mediated partial agonist activity.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2850923     DOI: 10.1016/0014-2999(88)90543-2

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  17 in total

1.  Buprenorphine and opioid antagonism, tolerance, and naltrexone-precipitated withdrawal.

Authors:  Carol A Paronis; Jack Bergman
Journal:  J Pharmacol Exp Ther       Date:  2010-11-04       Impact factor: 4.030

Review 2.  Buprenorphine in cancer pain.

Authors:  Mellar P Davis
Journal:  Support Care Cancer       Date:  2005-07-12       Impact factor: 3.603

3.  Benzodiazepines and alcohol are associated with cases of fatal buprenorphine poisoning.

Authors:  Margareeta Häkkinen; Terhi Launiainen; Erkki Vuori; Ilkka Ojanperä
Journal:  Eur J Clin Pharmacol       Date:  2011-09-17       Impact factor: 2.953

4.  Attenuation of Antidepressant Effects of Ketamine by Opioid Receptor Antagonism.

Authors:  Nolan R Williams; Boris D Heifets; Christine Blasey; Keith Sudheimer; Jaspreet Pannu; Heather Pankow; Jessica Hawkins; Justin Birnbaum; David M Lyons; Carolyn I Rodriguez; Alan F Schatzberg
Journal:  Am J Psychiatry       Date:  2018-08-29       Impact factor: 18.112

5.  HS-599: a novel long acting opioid analgesic does not induce place-preference in rats.

Authors:  R Lattanzi; L Negri; E Giannini; H Schmidhammer; J Schutz; G Improta
Journal:  Br J Pharmacol       Date:  2001-09       Impact factor: 8.739

6.  Kappa antagonist properties of buprenorphine in non-tolerant and morphine-tolerant rats.

Authors:  S S Negus; M J Picker; L A Dykstra
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

7.  Serum Buprenorphine Concentrations and Behavioral Activity in Mice After a Single Subcutaneous Injection of Simbadol, Buprenorphine SR-LAB, or Standard Buprenorphine.

Authors:  Page H Myers; David R Goulding; Rebecca A Wiltshire; Christopher A McGee; Angela B Dickerson; Molly M Comins; Min Shi; Grace E Kissling; Fred B Lih; Leesa J Deterding; Kathy E Laber-Laird; Terry L Blankenship-Paris
Journal:  J Am Assoc Lab Anim Sci       Date:  2021-11-05       Impact factor: 1.232

8.  Buprenorphine: a unique drug with complex pharmacology.

Authors:  Kabirullah Lutfy; Alan Cowan
Journal:  Curr Neuropharmacol       Date:  2004-10       Impact factor: 7.363

Review 9.  The kappa-opiate receptor impacts the pathophysiology and behavior of substance use.

Authors:  David Mysels; Maria A Sullivan
Journal:  Am J Addict       Date:  2009 Jul-Aug

10.  Effects of indomethacin and buprenorphine analgesia on the postoperative recovery of mice.

Authors:  Michael D Blaha; Lisa R Leon
Journal:  J Am Assoc Lab Anim Sci       Date:  2008-07       Impact factor: 1.232

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.